| NASDAQ (NMS) Exchange | United States Country |
The fund is an investment vehicle that primarily focuses on the healthcare and biotechnology sectors, encompassing a variety of companies from the United States and abroad. It aims to invest a significant portion of its assets, at least 80%, in equity securities, including common and preferred stocks, as well as securities convertible into common stocks and warrants, of these healthcare and biotechnology companies, without a bias towards any specific market capitalization. The investment strategy is governed by a top-down approach, emphasizing long-term economic trends to guide its selections. This method allows the fund to identify and capitalize on global developments and sector dynamics that are expected to drive growth in the healthcare and biotechnology spaces.
This product focuses on investing in the common stocks, preferred stocks, convertible securities, and warrants of U.S. and foreign healthcare companies. The aim is to leverage the growth potential of the healthcare sector, driven by innovation, regulatory changes, and increasing demand for healthcare services worldwide.
Similar to its approach with healthcare companies, the fund invests in equity securities of biotechnology firms. These investments are directed at companies engaged in the research, development, and commercialization of innovative medical treatments and technologies. Biotechnology investments are chosen based on their potential for substantial growth, benefitting from advancements in science and increasing healthcare needs.
The fund's investment adviser employs a top-down approach to portfolio management. This strategy begins with an analysis of global economic trends, identifying those with the potential to significantly impact the healthcare and biotechnology sectors. The adviser then selects investments that are well-positioned to benefit from these trends over the long term, focusing on sustainable growth opportunities.